Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02559154Phase 4Unknown
- Sponsor
- Shanghai General Hospital
- Start
- Jul 2010
- Primary completion
- Oct 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Disease responses to treatment at 1 year. Status: unknown.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02559154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559154.